Trial Profile
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2019
Price :
$35
*
At a glance
- Drugs Amatuximab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Malignant-mesothelioma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Morphotek
- 12 Apr 2019 According to Eudra record the trial has been completed in spain
- 07 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.